Примери за използване на Treated with pioglitazone на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Use in patients treated with pioglitazone.
You can usually continue to take other medicines whilst you are being treated with Pioglitazone Teva.
It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes.
The risk of fractures should be considered in the long term care of women treated with pioglitazone.
Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials.
There was no tumourigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.
Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical studies.
There was no tumourigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.
No increase in fracture rates was observed in men treated with pioglitazone(1.3%) versus comparator(1.5%).
Available epidemiological data for pioglitazone suggest a small increased risk of bladder cancer in diabetic patients treated with pioglitazone.
No increase in fracture rates was observed in men treated with pioglitazone(1.3%) versus comparator(1.5%).
While a causal relationship between dapagliflozin and bladder cancer is unlikely(see sections 4.8 and 5.3), as a precautionary measure,Qtrilmet is not recommended for use in patients concomitantly treated with pioglitazone.
No increase in fracture rates was observed in men treated with pioglitazone(1.3%) versus comparator(1.5%).
While a causal relationship between dapagliflozin and bladder cancer is unlikely(see sections 4.8 and 5.3), as a precautionary measure,Qtern is not recommended for use in patients concomitantly treated with pioglitazone.
Post-marketing spontaneous reports of hypersensitivity reactions in patients treated with pioglitazone include anaphylaxis, angioedema, and urticaria.
While a causal relationship between dapagliflozin and bladder cancer is unlikely(see sections 4.8 and 5.3), as a precautionary measure,dapagliflozin is not recommended for use in patients concomitantly treated with pioglitazone.
At two years, glycaemic control(defined as HbA1c<8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide.
While a causal relationship between dapagliflozin and bladder cancer is unlikely(see sections 4.8 and 5.3), as a precautionary measure,this medicinal product is not recommended for use in patients concomitantly treated with pioglitazone.
At two years, glycaemic control(defined as HbA1c< 8.0%)was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide.
An increased incidence of hyperplasia(males and females) and tumours(males)of the urinary bladder epithelium was apparent in rats treated with pioglitazone for up to 2 years.
The incidence of fractures calculated per 100 patient-years was 1.9 fractures in women treated with pioglitazone and 1.1 fractures in treated women by a comparator.
The risk of fractures should be considered in the long term care of patients treated with pioglitazone(see section 4.8).
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator.
Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator.
Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.
The co-administration of alogliptin andpioglitazone has been studied as dual therapy in patients initially treated with pioglitazone alone(with or without metformin or a sulphonylurea) and as add-on therapy to metformin.
Some patients with longstanding type 2 diabetes and heart disease orprevious stroke who were treated with pioglitazone and insulin developed heart failure.
Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, although not all studies identified a statistically significant increased risk.
In a meta-analysis of 19 randomized, double-blind, placebo-controlled orcomparative studies involving 16,390 patients treated with pioglitazone, ranging from 4 months to 3.5 years, Lincoff et al.